MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


Yourgene Health first-half revenue up 5%; says Covid-19 testing expanding rapidly

StockMarketWire.com

Molecular diagnostics group Yourgene Health said its first-half revenue had risen 5%, as strong growth in Europe offset weakness in the company's international division.

Revenue for the six months through September increased to £8.2 million, up from £7.8 million year-on-year.

European revenue rose 80% and UK revenue rose 40%, while international revenue fell 25%, a drop the company pinned on the Covid-19 crisis.

Looking forward, Yourgene Health said core laboratory customers were now returning to more normal patterns of testing.

If the recovery was sustained, the company said it expected to see a restoration of previous growth trends in non-invasive prenatal testing, reproductive health, oncology and research markets.

Yourgene also said its UK Covid-19 testing service was expanding rapidly. From the beginning of October, it was operating at its full capacity of 10,000 tests per month.

Capacity was being further expanded to 20,000 tests per month, which was due to come on stream in the third quarter.

'This will increase Covid-19 testing revenue potential to approximately £1 million per month and there is potential for further expansion in line with anticipated demand,' the company said.

Chief executive Lyn Rees said that with the US and Japan now reopening for business, she expected to see international revenues growing rapidly around the company's core products.

'Our full year outlook remains in line with management expectations and we look forward to updating investors again when we publish our half-year results in December,' Rees said.



Story provided by StockMarketWire.com